ASAP1 and gastric cancer: Those GC patients with AMAP1 mRNA overexpression showed reduced overall survival (OS) compared to patients with low AMAP1 expression, according to the TCGA-STAD dataset (HR = 1.47, 95% CI: 1.04–2.08; P = 0.029; Supplementary Figure 1).